Sandoval, D
AHF, Hospital admission due to heart failure
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
Princeton, NJ: Novo Nordisk Inc
Some preproglucagon-expressing neurons in the nucleus tractus solitarius of the brain stem have also been shown to synthesise GLP-1 (2)
The following timeline, based on clinical trial data from Eli Lilly, shows the typical progression: Appetite suppression typically begins around day 3 of the first dose, with significant feelings of fullness developing by week 2
